After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...
LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...
In this piece, we will look at where Eli Lilly and Company (NYSE:LLY) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future ...
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...